Unknown

Dataset Information

0

Anti-CD3 antibody treatment induces hypoglycemia and super tolerance to glucose challenge in mice through enhancing glucose consumption by activated lymphocytes.


ABSTRACT: Anti-CD3 antibody has been employed for various immune-mediated disorders. However, whether anti-CD3 administration leads to rapid metabolic alternation has not been well investigated. In the current study, we studied how anti-CD3 treatment affected blood glucose levels in mice. We found that anti-CD3 treatment induced immediate reduction of blood glucose after administration. Furthermore, a single dose of anti-CD3 treatment corrected hyperglycemia in all nonobese diabetic mice with recently diagnosed diabetes. This glucose-lowering effect was not attributable to major T cell produced cytokines. Of interest, when tested in a normal strain of mice (C57BL/6), the serum levels of C-peptide in anti-CD3 treated animals were significantly lower than control mice. Paradoxically, anti-CD3 treated animals were highly tolerant to exogenous glucose challenge. Additionally, we found that anti-CD3 treatment significantly induced activation of T and B cells in vitro and in vivo. Further studies demonstrated that anti-CD3 treatment lowered the glucose levels in T cell culture media and increased the intracellular transportation of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2 deoxyglucose (2-NBDG) particularly in activated T and B cells. In addition, injection of anti-CD3 antibodies induced enhanced levels of Glut1 expression in spleen cells. This study suggests that anti-CD3 therapy-induced hypoglycemia likely results from increased glucose transportation and consumption by the activated lymphocytes.

SUBMITTER: Xia CQ 

PROVIDER: S-EPMC3987876 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anti-CD3 antibody treatment induces hypoglycemia and super tolerance to glucose challenge in mice through enhancing glucose consumption by activated lymphocytes.

Xia Chang-Qing CQ   Chernatynskaya Anna V AV   Looney Benjamin B   Wan Suigui S   Clare-Salzler Michael J MJ  

Journal of immunology research 20140211


Anti-CD3 antibody has been employed for various immune-mediated disorders. However, whether anti-CD3 administration leads to rapid metabolic alternation has not been well investigated. In the current study, we studied how anti-CD3 treatment affected blood glucose levels in mice. We found that anti-CD3 treatment induced immediate reduction of blood glucose after administration. Furthermore, a single dose of anti-CD3 treatment corrected hyperglycemia in all nonobese diabetic mice with recently dia  ...[more]

Similar Datasets

| S-EPMC6470310 | biostudies-literature
| S-EPMC8102028 | biostudies-literature
| S-EPMC8015820 | biostudies-literature
| S-EPMC5851215 | biostudies-literature
| S-EPMC10538856 | biostudies-literature
| S-EPMC5999378 | biostudies-literature
| S-EPMC4114874 | biostudies-literature
| S-EPMC2978606 | biostudies-literature
| S-EPMC6014929 | biostudies-literature
| S-EPMC8417923 | biostudies-literature